Tricyclic fused heterocyclic PDE3 / 4 dual inhibitors and their uses
Dual PDE3/4 inhibitors with enhanced properties address the limitations of current COPD treatments by offering synergistic anti-inflammatory and bronchodilatory effects, improving therapeutic efficacy for COPD and asthma.
Patent Information
- Application Number
- JP2024534672
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-02-09
- Filing Date
- 2022-12-13
- Publication Date
- 2024-12-05
AI Technical Summary
Current COPD treatments, primarily relying on bronchodilators, only alleviate symptoms and do not provide a cure, while PDE3 and PDE4 selective inhibitors have limitations such as low solubility and insufficient anti-inflammatory effects, necessitating the development of dual PDE3/4 inhibitors with improved efficacy.
Development of compounds with high activity and physicochemical properties as PDE3/4 dual inhibitors, offering synergistic anti-inflammatory and bronchodilatory effects, with enhanced bioavailability and reduced toxic side effects.
The compounds demonstrate excellent formulation properties, high bioavailability, and low toxicity, providing effective treatment for COPD and asthma by targeting key pathological features with improved therapeutic outcomes.
Smart Images

Figure 2024545189000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to dual PDE3 / 4 inhibitors and their use in the manufacture of a medicament for the treatment of COPD and asthma. [Background technology]
[0002] COPD (chronic obstructive pulmonary disease) is a group of lung diseases characterized by airflow limitation, which is not completely reversible, but progressive, mainly affects the lungs, and is the most common chronic factor threatening pulmonary health. The incidence and mortality rate of COPD remain high because, on the one hand, early diagnosis of COPD is difficult, COPD always develops silently, and when clinical symptoms appear, a gradual decline in the patient's overall health and a gradual increase in respiratory symptoms are often predicted, and, on the other hand, COPD cannot be cured at present, and COPD drugs mainly rely on bronchodilators that can regulate the smooth muscles of the airways. Such medicines can only relieve symptoms and delay the worsening of the disease, but do not cure it. COPD has a long course, and patients sometimes need frequent consultations, hospitalization due to acute exacerbations, and long-term nursing care, occupying a large amount of medical resources, and is currently already a burden of troublesome diseases worldwide. Therefore, it is necessary to start from a different target and develop new medicines for COPD to meet different clinical needs.
[0003] Phosphodiesterase (PDE) belongs to the superfamily enzyme system, which includes 11 families, and each family is involved in different signal transduction and regulates different physiological processes. Research has shown that PDE3 is related to the contraction of smooth muscle in the respiratory system, and PDE4 plays an important role in immune cell-induced inflammatory response. Considering the limitations of PDE3 or PDE4 selective inhibitors in clinical practice, dual inhibitors of PDE3 / 4 are considered to be a more attractive way to target the key pathological features of COPD and asthma. At present, there has been evidence that PDE3 / 4 dual target inhibitors have synergistic inhibitory effects, including synergistic anti-inflammatory and bronchodilatory effects. WO 2000058308A1 reported that the compound RPL554 has long-acting bronchodilator and anti-inflammatory effects; however, the drug has low solubility and high plasma clearance, making it suitable for inhalation administration; and according to biological activity data, its PDE4 inhibitory activity is insufficient, and its anti-inflammatory effect may not be ideal; therefore, PDE3 / 4 dual inhibitors are still worth studying. Summary of the Invention [Means for solving the problem]
[0004] The present invention provides a compound of formula (I) or formula (II), a stereoisomer, a solvate, or a pharma- ceutically acceptable salt thereof, which has the excellent effects of high activity, physicochemical properties that facilitate formulation, high bioavailability, and low toxic side effects.
[0005] A compound of formula (I) or (II), a stereoisomer, solvate, or a pharma- ceutically acceptable salt thereof, [ka] Here, R1, R2, R a and R b are each independently H, deuterium, halogen, CN, OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl group, -O(CH2)m C 3-6 Cycloalkyl groups, -O(CH2) m Phenyl group, -O(CH2) m - a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O; -O(CH2) m - a 5-6 membered heteroaryl group containing 1-3 heteroatoms selected from N, S and O; 1-4 Alkyl group, -(CH2) m C 3-6 Cycloalkyl groups, -(CH2) m Phenyl group, -(CH2) m - a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, S, and O, or -(CH2) m - a 5-6 membered heteroaryl group containing 1-3 heteroatoms selected from N, S and O, the alkyl, phenyl, cycloalkyl, heterocycloalkyl and heteroaryl groups optionally containing deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4 Alkoxy groups, halogenated C 1-4 Alkoxy groups, CN, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 is further substituted with 1 to 3 groups selected from alkyl, In some embodiments, R, R, R a and R b are each independently H, deuterium, halogen, CN, OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl group, -O(CH2) m C 3-6 Cycloalkyl groups, -O(CH2) m - a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O; 1-4Alkyl group, -(CH2) m C 3-6 Cycloalkyl group, or -(CH2) m - a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O, the alkyl group, cycloalkyl group and heterocycloalkyl group optionally being deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4 Alkoxy and halogenated C 1-4 is further substituted with 1 to 3 groups selected from an alkoxy group; In some embodiments, R, R, R a and R b are each independently H, deuterium, halogen, CN, OH, -OC 1-4 Alkyl group, -O(CH2) m C 3-6 Cycloalkyl groups, C 1-4 Alkyl group, or -(CH2) m C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups optionally containing deuterium, halogen, C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4 Alkoxy and halogenated C 1-4 is further substituted with 1 to 3 groups selected from an alkoxy group; In some embodiments, R, R, R a and R b are each independently H, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, or -O(CH2) m Cyclopropyl, methyl, ethyl, propyl, isopropyl or -(CH2) ma cyclopropyl group, wherein the methoxy group, ethoxy group, propoxy group, isopropoxy group, cyclopropyl group, methyl group, ethyl group, propyl group, isopropyl group, and cyclopropyl group are optionally further substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, methyl group, ethyl group, propyl group, isopropyl group, methoxy group, ethoxy group, propoxy group, deuterated methyl group, deuterated ethyl group, deuterated propyl group, deuterated methoxy group, deuterated ethoxy group, deuterated propoxy group, halogenated methoxy group, halogenated ethoxy group, and halogenated propoxy group; Optionally, R1 and R2 and the atoms connected thereto are taken together to form a 5-7 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 4-7 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C 1-4 Alkyl groups, halogenated C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, R1 and R2 and the atoms connected thereto are taken together to form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 5-6 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C 1-4 Alkyl groups, halogenated C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, R1 and R2 and the atoms connected thereto are taken together to form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 5-6 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C1-4 Alkyl groups, halogenated C 1-4 Alkyl group and C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, R1 and R2 and the atoms connected thereto, taken together, are [ka] and optionally substituted with 1 to 2 groups selected from deuterium, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, halogenated methyl, halogenated ethyl and halogenated propyl groups; R3, R4, R5, and R6 are each independently H, deuterium, halogen, or C. 1-4 Alkyl group, -(CH2) m C 3-6 a cycloalkyl group, the alkyl group and the cycloalkyl group being optionally substituted with 1 to 3 groups selected from deuterium, halogen, CN, and NH; In some embodiments, R, R, R, and R are each independently selected from H, deuterium, halogen, and C. 1-4 an alkyl group, the alkyl group being optionally substituted with 1 to 3 groups selected from deuterium, halogen, CN, and NH; In some embodiments, R, R are each independently selected from H, deuterium, halogen, and C. 1-4 an alkyl group, the alkyl group being optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br and I; R5 and R6 are each independently H; In some embodiments, R3 and R4 are each independently H, deuterium, F, Cl, Br, I, a methyl group, an ethyl group, or a propyl group, and the methyl group, ethyl group, or propyl group is optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, and I; R5 and R6 are each independently H; Optionally, R and R, or R and R, together with the carbon atom to which they are attached, are C 3-6Forming a cycloalkyl group, X is CO or SO, and in some embodiments, X is CO; Ring A is a phenyl group, C 9-10 a fused carbocyclic ring or a 5-6 membered heteroaryl group containing 1-3 heteroatoms selected from N, S and O; In some embodiments, ring A is a phenyl group, [ka] (the linking site is any ring atom that follows the rules of chemical bonding in the ring), pyridyl, pyrimidinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl or isoxazolyl; In some embodiments, ring A is a phenyl group, [ka] (the linking site is any ring atom that follows the rules for chemical bonding in the ring), thienyl, thiazolyl, isothiazolyl, oxazolyl or isoxazolyl; In some embodiments, ring A is a phenyl group, [ka] (the linking site is any ring atom that follows the rules for chemical bonding in the ring), a thienyl group, or a thiazolyl group; L1 is C 1-6 an alkylene group, the alkylene group optionally containing deuterium, halogen, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, L is C 2-4 an alkylene group, the alkylene group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, L is C 2-4 is an alkylene group, R7 is H, C 1-4 Alkyl group or -(CH2) m C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups optionally containing deuterium, halogen, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, R7 is H or C 1-4 an alkyl group, the alkyl group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, R7 is H or C 1-3 an alkyl group, the alkyl group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, R7 is H, a methyl group, an ethyl group, a propyl group, or an isopropyl group, and the methyl group, the ethyl group, the propyl group, or the isopropyl group is optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, a methoxy group, an ethoxy group, a propoxy group, a deuterated methyl group, a deuterated ethyl group, a deuterated propyl group, a deuterated methoxy group, a deuterated ethoxy group, a deuterated propoxy group, a halogenated methoxy group, a halogenated ethoxy group, and a halogenated propoxy group; R8 and R9 are each independently H, C 1-4 Alkyl group and C3-6 is a cycloalkyl group, In some embodiments, R and R are each independently H; Optionally, R8 and R9 together with the N atom to which they are attached form a 5-6 membered heterocycle containing 1-3 heteroatoms selected from N, S, and O, the heterocycle optionally being selected from =O, deuterium, halogen, C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; In some embodiments, R8 and R9 together with the N atom to which they are attached form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms, the heterocycle optionally being selected from =O, deuterium, halogen, C 1-4 Alkyl group and C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; Each R 10 are each independently H, halogen, CN, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl)2, OH, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -(CH2) m -C 3-6 Cycloalkyl groups, -OC 3-6 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl groups, CN, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 substituted with 1 to 3 groups selected from alkyl)2 and OH; In some embodiments, each R 10 are each independently H, halogen, CN, or C1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 substituted with 1 to 3 groups selected from alkyl and CN; In some embodiments, each R 10 are each independently H, halogen, CN, or C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-4 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 substituted with 1 to 3 groups selected from alkyl and CN; In some embodiments, each R 10 are each independently H, F, Cl, Br, I, CN, methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, isobutyl group, vinyl group, propenyl group, allyl group, ethynyl group, propynyl group, cyclopropyl group, cyclobutyl group, methoxy group, ethoxy group, or propoxy group, and the methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, isobutyl group, vinyl group, propenyl group, allyl group, ethynyl group, propynyl group, cyclopropyl group, cyclobutyl group, methoxy group, ethoxy group, and propoxy group are optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, methyl group, ethyl group, propyl group, and CN; n is 0, 1, 2, 3 or 4; In some embodiments, n is 0, 1, 2, or 3; each m is independently 0, 1, 2, 3, or 4; In some embodiments, each m is independently 0, 1, 2, or 3; q is 2 or 3; As a condition, [ka] but [ka] If R 10 ', R 10 '', R 10 ''' is R 10 and the compound satisfies: (iv) R1 and R2 are not simultaneously methoxy groups, or (v) R3, R4, R5 and R6 are not H at the same time, or (vi)R 10 ''' is not H or a methyl group.
[0006] As a more specific first technical solution of the present invention, there is provided a compound represented by formula (I), a stereoisomer, a solvate, or a pharma- ceutically acceptable salt thereof, [ka] Here, R1, R2, R a and R b are each independently H, deuterium, halogen, CN, OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl group, -O(CH2) m C 3-6 Cycloalkyl groups, -O(CH2) m Phenyl group, -O(CH2) m - a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O; -O(CH2) m - a 5-6 membered heteroaryl group containing 1-3 heteroatoms selected from N, S and O; 1-4 Alkyl group, -(CH2) m C 3-6 Cycloalkyl groups, -(CH2) m Phenyl group, -(CH2)m - a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, S, and O, or -(CH2) m - a 5-6 membered heteroaryl group containing 1-3 heteroatoms selected from N, S and O, the alkyl, phenyl, cycloalkyl, heterocycloalkyl and heteroaryl groups optionally containing deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4 Alkoxy groups, halogenated C 1-4 Alkoxy groups, CN, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 is further substituted with 1 to 3 groups selected from alkyl, Optionally, R1 and R2 and the atoms connected thereto are taken together to form a 5-7 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 4-7 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C 1-4 Alkyl groups, halogenated C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R3, R4, R5, and R6 are each independently H, deuterium, halogen, or C. 1-4 Alkyl group, -(CH2) m C 3-6 a cycloalkyl group, the alkyl group and the cycloalkyl group being optionally substituted with 1 to 3 groups selected from deuterium, halogen, CN, and NH; Optionally, R and R, or R and R, together with the carbon atom to which they are attached, are C 3-6 Forming a cycloalkyl group, X is CO or SO2; Ring A is a phenyl group, C 9-10 a fused carbocyclic ring or a 5-6 membered heteroaryl group containing 1-3 heteroatoms selected from N, S and O; L1 is C 1-6 an alkylene group, the alkylene group optionally containing deuterium, halogen, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R7 is H, C 1-4 Alkyl group or -(CH2) m C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups optionally containing deuterium, halogen, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R8 and R9 are each independently H, C 1-4 Alkyl group and C 3-6 is a cycloalkyl group, Optionally, R8 and R9 together with the N atom to which they are attached form a 5-6 membered heterocycle containing 1-3 heteroatoms selected from N, S, and O, the heterocycle optionally being selected from =O, deuterium, halogen, C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; Each R 10 are each independently H, halogen, CN, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl)2, OH, C 1-4 Alkyl group, C 2-4Alkenyl group, C 2-4 Alkynyl group, -(CH2) m -C 3-6 Cycloalkyl groups, -OC 3-6 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl groups, CN, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 substituted with 1 to 3 groups selected from alkyl)2 and OH; n is 0, 1, 2, 3 or 4; each m is independently 0, 1, 2, 3, or 4; As a condition, [ka] but [ka] If R 10 ', R 10 '', R 10 ''' is R 10 and the compound satisfies: (vii) R1 and R2 are not simultaneously methoxy groups, or (viii) R3, R4, R5 and R6 are not simultaneously H, or (ix) R 10 ''' is not H or a methyl group.
[0007] As a more specific second technical solution of the present invention, there is provided a compound of formula I, its stereoisomer, solvate, or pharma- ceutically acceptable salt, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R a and R b are each independently H, deuterium, halogen, CN, OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl)2, -OC1-4 Alkyl group, -O(CH2) m C 3-6 Cycloalkyl groups, -O(CH2) m - a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O; 1-4 Alkyl group, -(CH2) m C 3-6 Cycloalkyl group, or -(CH2) m - a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O, the alkyl group, cycloalkyl group and heterocycloalkyl group optionally being deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4 Alkoxy and halogenated C 1-4 is further substituted with 1 to 3 groups selected from an alkoxy group; Optionally, R1 and R2 and the atoms connected thereto are taken together to form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 5-6 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C 1-4 Alkyl groups, halogenated C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R3, R4, R5, and R6 are each independently H, deuterium, halogen, or C 1-4 an alkyl group, the alkyl group being optionally substituted with 1 to 3 groups selected from deuterium, halogen, CN, and NH; Ring A is a phenyl group, [ka] , a pyridyl group, a pyrimidinyl group, a thienyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group or an isoxazolyl group, L1 is C 2-4 an alkylene group, the alkylene group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R7 is H or C 1-4 an alkyl group, the alkyl group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R8 and R9 are each independently H, C 1-4 Alkyl group and C 3-6 is a cycloalkyl group, Optionally, R8 and R9 together with the N atom to which they are attached form a 5-6 membered heterocycle containing 1-3 heteroatoms selected from N, S, and O, the heterocycle optionally being selected from =O, deuterium, halogen, C 1-4 Alkyl group and C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; Each R 10 are each independently H, halogen, CN, or C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 substituted with 1 to 3 groups selected from alkyl and CN; p is 1 or 2; The rest is as described in the first technical proposal.
[0008] As a more specific third technical solution of the present invention, there is provided a compound of formula I, its stereoisomer, solvate, or pharma- ceutically acceptable salt, wherein the compound has the structure of formula II: [ka] R1, R2, R a and R b are each independently H, deuterium, halogen, CN, OH, -OC 1-4 Alkyl group, -O(CH2) m C 3-6 Cycloalkyl groups, C 1-4 Alkyl group, or -(CH2) m C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups optionally containing deuterium, halogen, C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4 Alkoxy and halogenated C 1-4 is further substituted with 1 to 3 groups selected from an alkoxy group; Optionally, R1 and R2 and the atoms connected thereto are taken together to form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 5-6 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C 1-4 Alkyl groups, halogenated C 1-4 Alkyl group and C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R3 and R4 are each independently H, deuterium, halogen, or C. 1-4 an alkyl group, the alkyl group being optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, and I; Ring A is a phenyl group, [ka] , thienyl, thiazolyl, isothiazolyl, oxazolyl or isoxazolyl; R7 is H or C1-3 an alkyl group, the alkyl group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; Each R 10 are each independently H, halogen, CN, or C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-4 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 substituted with 1 to 3 groups selected from alkyl and CN; q is 1, 2 or 3; The rest is as described in the second technical proposal.
[0009] As a more specific fourth technical solution of the present invention, there is provided a compound of formula II, its stereoisomer, solvate, or pharma- ceutically acceptable salt, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R a and R b are each independently H, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, or -O(CH2) m Cyclopropyl, methyl, ethyl, propyl, isopropyl or -(CH2) m a cyclopropyl group, wherein the methoxy group, the ethoxy group, the propoxy group, the isopropoxy group, the cyclopropyl group, the methyl group, the ethyl group, the propyl group, the isopropyl group, and the cyclopropyl group are optionally further substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, a methyl group, an ethyl group, a propyl group, an isopropyl group, a methoxy group, an ethoxy group, a propoxy group, a deuterated methyl group, a deuterated ethyl group, a deuterated propyl group, a deuterated methoxy group, a deuterated ethoxy group, a deuterated propoxy group, a halogenated methoxy group, a halogenated ethoxy group, and a halogenated propoxy group; Optionally, R1 and R2 and the atoms connected thereto together represent: [ka] and optionally substituted with 1 to 2 groups selected from deuterium, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, halogenated methyl, halogenated ethyl and halogenated propyl groups; R3 and R4 are each independently H, deuterium, F, Cl, Br, I, a methyl group, an ethyl group, or a propyl group, and the methyl group, ethyl group, or propyl group is optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, and I; Ring A is a phenyl group, [ka] , a thienyl group or a thiazolyl group; R7 is H, a methyl group, an ethyl group, a propyl group, or an isopropyl group, and the methyl group, the ethyl group, the propyl group, or the isopropyl group is optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, a methoxy group, an ethoxy group, a propoxy group, a deuterated methyl group, a deuterated ethyl group, a deuterated propyl group, a deuterated methoxy group, a deuterated ethoxy group, a deuterated propoxy group, a halogenated methoxy group, a halogenated ethoxy group, and a halogenated propoxy group; Each R 10are each independently H, F, Cl, Br, I, CN, methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, isobutyl group, vinyl group, propenyl group, allyl group, ethynyl group, propynyl group, cyclopropyl group, cyclobutyl group, methoxy group, ethoxy group, or propoxy group, and the methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, isobutyl group, vinyl group, propenyl group, allyl group, ethynyl group, propynyl group, cyclopropyl group, cyclobutyl group, methoxy group, ethoxy group, and propoxy group are optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, methyl group, ethyl group, propyl group, and CN; q is 2 or 3; The rest is as described in the third technical proposal.
[0010] As a more specific fifth technical solution of the present invention, there is provided a compound according to formula I, its stereoisomer, solvate, or pharma- ceutically acceptable salt, wherein the compound is: [ka] [ka] is selected from one of the structures:
[0011] As a more specific sixth technical solution of the present invention, a pharmaceutical composition is provided, which contains a compound described in any one of the first to fifth technical solutions, a stereoisomer, a solvate, or a pharma- ceutically acceptable salt thereof, and a pharma-ceutically acceptable carrier and / or excipient.
[0012] As a more specific seventh technical solution of the present invention, there is provided a use, i.e., a use of a compound described in any one of the first to fifth technical solutions, its stereoisomer, solvate, or pharma- ceutically acceptable salt, or a composition described in the sixth technical solution, in the manufacture of a pharmaceutical for treating / preventing a PDE3 / 4-mediated disease.
[0013] Further, said PDE3 / 4 mediated disease is selected from COPD and asthma.
[0014] Synthetic Route Those skilled in the art can combine known organic synthesis techniques to prepare the compounds of the present invention, and the starting materials are commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" are obtained from legitimate commercial sources, including companies such as Taitan Technology, Ananji Chemical, Shanghai Demo, Chengdu Kelong Chemical, Shaoyuan Chemical Technology, Nanjing Yaoshi, Yaoming Kangde and Bailingwei Technology.
[0015] Reference texts and treatises in the field provide detailed introductions to the synthesis of reactants that can be used to prepare the compounds described herein, or provide texts describing such methods for reference. These references and treatises include: "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; SR Sandler et al., "Organic Functional Group Preparations", 2nd Ed., Academic Press, New York, 1983; HO House, "Modern Synthetic Reactions", 2nd Ed., WA Benjamin, Inc. Menlo Park, Calif. 1972; TL Gilchrist, "Heterocyclic Chemistry'', 2nd Ed., John Wiley & Sons, New York, 1992; J. March, ``Advanced Organic Chemistry: Reactions, Mechanisms and Structure'', 4th Ed., Wiley-Interscience, New York, 1992; Fuhrhop, J. and Penzlin G. ``Organic Synthesis: Concepts, Methods, Starting Materials'', Second, Revised and Enlarged Edition(1994)John Wiley & Sons ISBN: 3-527-29074-5; Hoffman,RV "Organic Chemistry,An Intermediate Text" (1996)Oxford University Press,ISBN 0-19-509618-5;Larock,RC "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition(1999)Wiley-VCH,ISBN: 0-471-19031-4; March,J.『Advanced Organic Chemistry: Reactions,Mechanisms,and Structure』 4th Edition(1992)John Wiley & Sons,ISBN: 0-471-60180-2; Otera,J.(editor)『Modern Carbonyl Chemistry』(2000)Wiley-VCH,ISBN: 3-527-29871-1; Patai,S. 『Patai’s 1992 Guide to the Chemistry of Functional Groups』(1992)Interscience ISBN: 0-471-93022-9; Solomons,T. W. G. 『Organic Chemistry』 7th Edition(2000)John Wiley & Sons,ISBN: 0-471-19095-0; Stowell,J.C.,『Intermediate Organic Chemistry』 2nd Edition(1993)Wiley-Interscience,ISBN: 0-471-57456-2; 『Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann’s Encyclopedia』(1999)John Wiley & Sons,ISBN: 3-527-29645-X,in 8 volumes; 『Organic Reactions』(1942-2000)John Wiley & Sons,in over 55 volumes; and 『Chemistry of Functional Groups』 John Wiley & Sons,in 73 volumes。.
[0016] Specific and similar reactants can be selectively identified by indexes of known chemicals produced by the Chemical Information Retrieval Service of the American Chemical Society, which are available in many public and university libraries and online. Chemicals that are known but not available in catalogs can optionally be produced by custom chemical synthesis businesses, many of which provide custom synthesis services, such as those listed above. A reference for producing and selecting pharmaceutical salts of the compounds described herein is PH Stahl & CG Wermuth, "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.
[0017] term Unless otherwise specified in the present invention, the terms used in the present invention have the following meanings.
[0018] Any carbon, hydrogen, oxygen, sulfur, nitrogen or halogen in the groups and compounds described herein includes its isotope, and any carbon, hydrogen, oxygen, sulfur, nitrogen or halogen in the groups and compounds described herein is optionally further replaced by one or more corresponding isotopes, where the carbon isotope is: 12 C and 13 C and 14 C; isotopes of hydrogen include protium (H), deuterium (also called heavy hydrogen), and tritium (T, also called tritium); isotopes of oxygen include 16 O and 17 O and 18 The isotopes of sulfur include 32 S and 33 S and 34 S and 36 S and the nitrogen isotopes are 14 N and 15 N and the fluorine isotope is 19 F, and the chlorine isotope is 35 Cl and 37 The isotopes of bromine include Cl and 79Br and 81 Includes Br.
[0019] As used herein, "halogen" refers to F, Cl, Br, I, or isotopes thereof.
[0020] "Halogenated" or "halogen substituted" refers to a group being substituted with one or more selected from F, Cl, Br, I, or isotopes thereof, the upper limit of the number of halogen substituents is equal to the sum of the replaceable hydrogens of the group being substituted, and unless otherwise limited, the number of halogen substituents is any integer between 1 and the upper limit, and when the number of halogen substituents is greater than 1, they may be substituted with the same or different halogens. Usually, cases of 1 to 5 halogen substitutions, 1 to 4 halogen substitutions, 1 to 3 halogen substitutions, 1 to 2 halogen substitutions, and 1 halogen substitution are included.
[0021] "Deuterium" refers to heavy hydrogen, an isotope of hydrogen (H), and has the same meaning as "D."
[0022] "Deuterated" or "deuterated product" refers to a case where a hydrogen atom in a group such as an alkyl group, a cycloalkyl group, an alkylene group, an aryl group, a heteroaryl group, a mercapto group, a heterocycloalkyl group, an alkenyl group, or an alkynyl group is replaced with at least one deuterium atom, and the upper limit of the number of deuteration is equal to the sum of the number of hydrogen atoms that can be replaced in the group to be replaced, and unless otherwise specified, the number of deuteration is any integer between 1 and the upper limit. For example, 1 to 20 deuterium atom substitutions, 1 to 10 deuterium atom substitutions, 1 to 6 deuterium atom substitutions, 1 to 3 deuterium atom substitutions, 1 to 2 deuterium atom substitutions, or 1 deuterium atom substitution.
[0023] "C x-y " group refers to a group containing x to y carbon atoms, e.g., "C 1-6 "Alkyl group" refers to an alkyl group containing from 1 to 6 carbon atoms.
[0024] "Alkyl group" refers to a monovalent linear or branched saturated aliphatic hydrocarbon group. Typically, the alkyl group has 1 to 20 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and the like, and the alkyl group may be further substituted with a substituent.
[0025] "Alkylene group" refers to divalent straight and branched chain saturated alkyl groups. Examples of alkylene groups include, but are not limited to, methylene groups, ethylene groups, and the like.
[0026] A "halogenated alkyl group" refers to a case where one or more hydrogens in an alkyl group are replaced with one or more halogen atoms (e.g., fluorine, chlorine, bromine, iodine, or isotopes thereof), and the upper limit of the number of halogen substituents is equal to the sum of the replaceable hydrogens in the alkyl group, and unless otherwise limited, the number of halogen substituents is any integer between 1 and the upper limit. Usually, the alkyl group is substituted with 1 to 5 halogens, or substituted with 1 to 3 halogens, or substituted with 1 to 2 halogens, or substituted with 1 halogen, and when the number of halogen substituents is greater than 1, they may be substituted with the same or different halogens, and specific examples include, but are not limited to, -CF3, -CH2Cl, -CH2CF3, -CCl2, CF3, etc.
[0027] An "alkoxy group" or an "alkyloxy group" refers to an -O-alkyl group. For example, -OC 1-8 Alkyl group, -OC 1-6 Alkyl group, -OC 1-4 Alkyl group or -OC 1-2Specific non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy, cyclopropoxy, and cyclobutoxy, and the alkoxy group may be optionally substituted with a substituent.
[0028] "Halogenated alkoxy group" refers to an -O-halogenated alkyl group. For example, -O-halogenated C 1-8 Alkyl groups, -O-halogenated C 1-6 Alkyl groups, -O-halogenated C 1-4 Alkyl group or -O-halogenated C 1-2 It is an alkyl group, and the upper limit of the number of halogen substituents is equal to the sum of the replaceable hydrogens of the substituted group. Unless otherwise specified, the number of halogen substituents is any integer between 1 and the upper limit, and is preferably 1 to 5 halogen substitutions, 1 to 3 halogen substitutions, 1 to 2 halogen substitutions, or 1 halogen substitution. When the number of halogen substituents is greater than 1, they may be substituted with the same or different halogens. Non-limiting examples include a monofluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a difluoroethyloxy group, etc.
[0029] The term "alkenyl group" refers to a straight-chain or branched-chain hydrocarbon group containing at least one carbon-carbon double bond (C=C), and typically contains 2 to 18 carbon atoms, for example, 2 to 8 carbon atoms, further for example, 2 to 6 carbon atoms, further for example, 2 to 4 carbon atoms, and examples thereof include vinyl groups, allyl groups, 1-propenyl groups, 2-propenyl groups, 1-butenyl groups, 2-butenyl groups, 3-butenyl groups, 1-pentenyl groups, 2-pentenyl groups, 3-pentenyl groups, 4-pentenyl groups, 1-methyl-1-butenyl groups, 2-methyl-1-butenyl groups, 2-methyl-3-butenyl groups, and the like. The alkenyl groups may be optionally further substituted with substituents, including, but not limited to, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene, and 1,4-hexadiene.
[0030] "Alkenylene group" refers to a straight or branched chain divalent unsaturated hydrocarbon group containing at least one carbon-carbon double bond (C=C), and unless otherwise specified, an alkynylene group contains from 2 to 6 carbon atoms, preferably from 2 to 4 carbon atoms; non-limiting examples include ethynylene groups, which may be optionally substituted with substituents.
[0031] The term "alkynyl group" refers to a straight chain or branched chain hydrocarbon group containing at least one carbon-carbon triple bond (C≡C), and typically containing 2 to 18 carbon atoms, further containing 2 to 8 carbon atoms, further containing 2 to 6 carbon atoms, and further containing 2 to 4 carbon atoms. Examples of the alkynyl group include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 4-pentyl, 3-pentyl, 1-methyl-2-butynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, and 4-decynyl, and the like, which may be optionally substituted with a substituent.
[0032] "Alkynylene group" refers to a straight or branched chain divalent unsaturated hydrocarbon group containing a carbon-carbon triple bond (C≡C) and typically containing from 2 to 6 carbon atoms, and more typically containing from 2 to 4 carbon atoms, non-limiting examples include ethynylene, propynylene, and butynylene groups, which alkynylene groups may be optionally substituted with substituents.
[0033] "Cycloalkyl group" refers to a saturated or partially unsaturated, non-aromatic carbocyclic hydrocarbon group that does not contain a cycloheteroatom. Cycloalkyl groups may be monocyclic, bicyclic or polycyclic, which may be parallel, spirocyclic, bridged or combinations thereof, and which may contain one or more aromatic rings, although the ring system as a whole does not have aromatic character and the linking site may be on an aromatic or non-aromatic ring. Typically, a cycloalkyl group contains 3 to 20 carbon atoms, further contains 3 to 8 carbon atoms, further contains 3 to 6 carbon atoms, if it is a monocyclic cycloalkyl group, it contains 3 to 15 carbon atoms, or 3 to 10 carbon atoms, or 3 to 8 carbon atoms, or 3 to 6 carbon atoms, if it is a bicyclic or polycyclic cycloalkyl group, it contains 5 to 12 carbon atoms, or 5 to 11 carbon atoms, or 6 to 10 carbon atoms, non-limiting examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, butenyl, cyclopentenyl, cyclohexenyl, [ka] and the like, where cycloalkyl groups may be optionally substituted with substituents.
[0034] A "cycloalkylene group" is a divalent group of a cycloalkyl group.
[0035] "Aryl group" refers to a carbocyclic ring having aromatic character and containing no heteroatoms, including monocyclic aryl groups and fused ring aryl groups. Typically contains 6 to 13 carbon atoms, more preferably 6 to 9 carbon atoms, and more preferably phenyl groups, non-limiting examples include phenyl, naphthyl, anthryl, and phenanthryl groups, and aryl groups may be optionally substituted with substituents.
[0036] "Carbocycle" or "carbocyclic group" refers to a saturated, partially unsaturated, or aromatic carbocycle, the meaning of which includes aryl and cycloalkyl groups. A carbocycle may be monocyclic, bicyclic, or polycyclic, which includes bridged, parallel, and spiro rings, and combinations thereof. A carbocycle typically has 3 to 12 carbon atoms, or 3 to 10 carbon atoms, or 3 to 6 carbon atoms. In non-limiting examples, monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or phenyl, and the like, and bicyclic bridged rings include [ka] and the like, and the bicyclic parallel ring is [ka] and the like, and the bicyclic spiro ring is [ka] etc., wherein the carbocycle may be optionally substituted with a substituent.
[0037] "Heterocycloalkyl group" refers to a saturated or partially unsaturated non-aromatic carbocyclic ring containing 1, 2, 3, or 4 heteroatoms selected from N, S, and O. Heterocycloalkyl groups may be monocyclic, bicyclic, or polycyclic, and bicyclic or polycyclic rings may be bridged, parallel, spiro, or combinations thereof, and bicyclic or polycyclic rings may contain one or more aromatic or heteroaromatic rings, but the ring system as a whole may not have aromaticity and the linking site may be on an aromatic or non-aromatic ring. Heterocycloalkyl groups are usually 3-20 membered rings, and when they are monocyclic heterocycloalkyl groups, they are usually 3-15 membered, or 3-10 membered, or 3-8 membered, or 3-6 membered, and when they are bicyclic or polycyclic heterocycloalkyl groups, they are usually 5-12 membered, or 5-11 membered, or 6-9 membered. Here, the heteroatoms N and S include their oxidation states. Non-limiting examples of heterocycloalkyl groups include azetidinyl, morpholinyl, piperazinyl, piperidinyl, tetrahydropyranyl, oxetanyl, pyranyl, azacyclopentenyl, azacyclohexenyl, oxolyl, oxynyl groups, and the like, and heterocycloalkyl groups may be optionally substituted with substituents.
[0038] "Heteroaromatic ring" or "heteroaryl group", unless otherwise specified, refers to a ring containing 1 to 4 heteroatoms selected from N, O, or S and their oxidation states, and having aromaticity, which may be monocyclic, bicyclic, or polycyclic, and the bicyclic or polycyclic ring may be bridged, parallel, spiro, or combinations thereof, and if bicyclic or polycyclic, may be a condensation of a heteroaryl group with an aryl group, or a condensation of a heteroaryl group with a heteroaryl group, where both the heteroaryl group or the aryl group may be linking moieties. Non-limiting examples include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, purinyl, [ka] and the like, wherein said heteroaryl groups may be optionally substituted with substituents.
[0039] "Heterocyclo" or "heterocyclo group" refers to a saturated or unsaturated aromatic or non-aromatic ring containing 1 to 4 heteroatoms selected from N, O, or S and their oxidation states, including heteroaryl and heterocycloalkyl groups. Heterocyclo includes monocyclic heterocyclo, bridged bicyclic heterocyclo, fused bicyclic heterocyclo, and spiro bicyclic heterocyclo or combinations thereof. Typically, it is a 3- to 12-membered heterocyclo or a 5- to 12-membered heterocyclo, or a 5- to 7-membered heterocyclo. Heterocyclo groups may be attached at a heteroatom or a carbon atom, non-limiting examples being oxiranyl, azacyclopropyl, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxanyl, piperazinyl, azacycloheptyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihydrofuranyl, and the like. an aryl group, a dihydropyranyl group, a dithiolanyl group, a tetrahydrofuranyl group, a tetrahydropyrrolyl group, a tetrahydroimidazolyl group, an oxazolyl group, a dihydrooxazolyl group, a tetrahydrooxazolyl group, a tetrahydrothiazolyl group, a tetrahydropyranyl group, a benzimidazolyl group, a benzopyridyl group, a pyrrolopyridyl group, a benzodihydrofuryl group, an azabicyclo[3.2.1]octyl group, an azabicyclo[5.2.0]nonyl group, an oxatricyclo[5.3.1.1]dodecyl group, an azaadamantyl group, and an oxaspiro[3.3]heptyl group; [ka] and the like, heterocyclos may be optionally substituted with substituents.
[0040] A "heterocyclylene group" refers to a substituted or unsubstituted, saturated or unsaturated, aromatic or non-aromatic divalent heterocyclo group. Non-limiting examples include: [ka] etc.
[0041] "Spiro ring" refers to a polycyclic group in which the rings share one carbon atom (called a spiro atom), which may contain zero or more double or triple bonds and zero to five heteroatoms selected from N, O, S, P, Si and their oxidation states. Typically, the spiro ring is a 6-14 membered ring, or a 6-12 membered ring, or a 6-10 membered ring. Typically, the spiro ring is a 3 spiro 3 (representing a 3-membered spiro 3-membered ring), a 3 spiro 4, a 3 spiro 5, a 3 spiro 6, a 4 spiro 4, a 4 spiro 5, a 4 spiro 6, a 5 spiro 5, or a 5 spiro 6. Non-limiting examples of spiro rings are: [ka] wherein said spiro ring may be optionally substituted with a substituent.
[0042] "Parallel ring" refers to a polycyclic group in which the rings share two adjacent ring atoms and one chemical bond, and may contain one or more double or triple bonds, and the parallel ring may contain 0-5 heteroatoms selected from N, S, O, P, Si and their oxidation states. Usually, the parallel ring is a 5-20 membered ring, or a 5-14 membered ring, or a 5-12 membered ring, or a 5-10 membered ring. Usually, the parallel ring is a 3-parallel 4 ring (representing a parallel ring formed of a 3-membered ring and a 4-membered ring, and based on the IUPC naming rules, a parallel ring with a 3-membered ring as the base ring is possible, and a parallel ring with a 4-membered ring as the base ring is also possible, and the same applies below), a 3-parallel 5 ring, a 3-parallel 6 ring, a 4-parallel 4 ring, a 4-parallel 5 ring, a 4-parallel 6 ring, a 5-parallel 5 ring, a 5-parallel 6 ring, or a 6-parallel 6 ring. Non-limiting examples of parallel rings include purine, quinoline, isoquinoline, benzopyran, benzofuran, benzothiophene, [ka] wherein the parallel rings may be optionally substituted with substituents.
[0043] "Bridged ring" refers to two rings sharing two non-adjacent ring atoms and may contain one or more double or triple bonds. Bridged rings may contain 0-5 heteroatoms selected from N, S, O, P, Si and their oxidation states. Typically, the bridged ring has 5-20, or 5-14, or 5-12, or 5-10 ring atoms. Non-limiting examples of bridged rings include adamantane, [ka] wherein said bridging ring may be optionally substituted with a substituent.
[0044] "Substituted" or "substituent" means that, unless otherwise specified, any substitution occurs at any chemically permissible position, and the number of substituents complies with the rules of chemical bonding. Exemplary substituents are: 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 3-8 Heteroalkyl groups, C 5-12 Aryl group, 5-12 membered heteroaryl group, hydroxy group, C 1-6 Alkoxy group, C 5-12 Aryloxy group, thiol group, C 1-6 Alkylthio group, cyano group, halogen, C 1-6 Alkylthiocarbonyl group, C 1-6 Alkylcarbamoyl group, N-carbamoyl group, nitro group, silyl group, sulfinyl group, sulfonyl group, sulfoxide, halogenated C 1-6 Alkyl groups, halogenated C 1-6 Alkoxy group, amino group, phosphonic acid, -CO2(C 1-6 alkyl group), -OC(=O)(C 1-6 alkyl group), -OCO2(C 1-6 alkyl group), -C(=O)NH2, -C(=O)N(C 1-6 alkyl group)2, -OC(=O)NH(C 1-6 alkyl group), -NHC(=O)(C 1-6alkyl group), -N(C 1-6 Alkyl group)C(=O)(C 1-6 alkyl group), -NHCO2(C 1-6 alkyl group), -NHC(=O)N(C 1-6 alkyl group)2, -HC(=O)NH(C 1-6 alkyl group), -NHC(=O)NH2, -NHSO2(C 1-6 Alkyl group), -SO2N(C 1-6 Alkyl group)2, -SO2NH(C 1-6 Alkyl group), -SO2NH2, -SO2C 1-6 These include, but are not limited to, alkyl groups and the like.
[0045] "Optionally" or "optionally" means that the subsequently described event or circumstance may, but does not necessarily, occur, and the description includes both cases where the event or circumstance occurs and cases where it does not occur. For example, "an alkyl group optionally substituted with F" means that the alkyl group may, but does not necessarily, be substituted with F, and indicates that the alkyl group is substituted with F and the alkyl group is not substituted with F.
[0046] "Pharmaceutically acceptable salts" refers to salts in which the compounds of the present invention retain the biological effectiveness and properties of the free acids or free bases and which are obtained by reaction of said free acids with non-toxic inorganic or organic bases, or by reaction of said free bases with non-toxic inorganic or organic acids.
[0047] A "pharmaceutical composition" refers to a mixture of one or more of the compounds herein or a stereoisomer, solvate, pharma- ceutically acceptable salt, or co-crystal thereof, with other components, wherein the other components include physiologically / pharmaceutical acceptable carriers and / or excipients.
[0048] The term "carrier" refers to a system that does not significantly stimulate the living body, does not eliminate the biological activity and properties of a given compound, and can change the administration form and distribution of a drug in the human body, control the release rate of the drug, and deliver the drug to a target organ. Non-limiting examples include microcapsules and microspheres, nanoparticles, liposomes, etc.
[0049] "Excipient" refers to a substance that is not a therapeutic agent itself, but is added to a pharmaceutical composition as a diluent, adjuvant, adhesive and / or vehicle to improve its processing or storage properties, or to permit or facilitate the compound or pharmaceutical composition to form a dosage form for administration. As known to those skilled in the art, pharmaceutical excipients can serve a variety of functions and may be described as wetting agents, buffers, suspending aids, lubricants, emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavoring agents and sweeteners. Examples of pharmaceutical excipients include, but are not limited to, the following: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, and crosslinked carboxymethylcellulose (e.g., crosslinked sodium carboxymethylcellulose); (4) tragacanth powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter, suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, goa oil, olive oil, and olive oils. (10) glycols, such as propylene glycol, (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol, (12) esters, such as ethyl oleate and ethyl laurate, (13) agar, (14) buffers, such as magnesium hydroxide and aluminum hydroxide, (15) alginic acid, (16) water for endotoxin testing, (17) isotonic saline, (18) Ringer's solution; (19) ethanol, (20) pH buffer solutions, (21) polyesters, polycarbonates, and / or polyanhydrides, and (22) other non-toxic, compatible substances used in pharmaceutical formulations.
[0050] "Stereoisomer" refers to isomers that result from different ways in which atoms are arranged in molecules, and includes cis-trans isomers, enantiomers and conformational isomers.
[0051] The compounds of the present invention further include tautomers thereof, for example, when a left-hand compound in which the pyrimidine ring is substituted with OH is described in the present invention, the right-hand tautomeric compound is also included. [ka]
[0052] The term "solvate" refers to a substance formed by intermolecular non-covalent bonding of the compound of the present invention or a salt thereof with a stoichiometric or non-stoichiometric solvent. When the solvent is water, it becomes a hydrate.
[0053] "Cocrystal" refers to a crystalline body formed by the association of an active pharmaceutical ingredient (API) and a cocrystal former (CCF) through the action of hydrogen bonds or other non-covalent bonds, where the API and CCF are both solids in their pure state at room temperature, and there is a fixed stoichiometric ratio between each component. Cocrystals are multi-component crystalline bodies, and include not only binary cocrystals formed between two neutral solids, but also multi-component cocrystals formed between a neutral solid and a salt or solvate. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0054] The present invention will be described in detail below with reference to examples. Unless specific conditions are specified in the examples, the experiments were carried out according to general conditions. The examples given are for better illustrating the present invention, and it should be understood that the present invention is not limited to the examples given. Non-essential improvements and adjustments made to the embodiments by those skilled in the art based on the above invention still fall within the scope of protection of the present invention. EXAMPLES
[0055] Example 1: (E)-1-(2-(2-(2,4,6-trimethylphenylimino)-10-methoxy-9-(methoxy-d3)-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (Compound 1) [ka]
[0056] Step 1: Compound 2-(3-(benzyloxy)-4-methoxyphenyl)eth-1-amino (1A) (synthesized with reference to the method described in J. Med. Chem. 2013,56,23,9673-9682) (51.5g, 0.20mol) was dissolved in water (300mL), potassium cyanate (32.4g, 0.40mol) was added little by little, and after uniform stirring, 2N hydrochloric acid (240mL) was added dropwise. After the dropwise addition was completed, the mixture was refluxed overnight. It was cooled to 0℃, filtered, and the filter cake was rinsed with ice ethanol and dried to obtain the target compound 1B (38.0g, yield 63%).
[0057] LC-MS(ESI): m / z=301.2 [M+H] + .
[0058] Step 2: Compound 1B (38g, 0.13mol) was dissolved in anhydrous ethanol (300mL) and diethyl malonate (27g, 0.17mol) was added. After the system was stirred uniformly, sodium ethoxide (133g, 0.39mol, 20wt% in EtOH) was added dropwise. After the addition was completed, the mixture was refluxed overnight, concentrated under reduced pressure to 150mL, diluted with water (150mL), and adjusted to pH 6.0 with 5N hydrochloric acid, then filtered. The filter cake was washed with water (150mL) and dried to obtain the target compound 1C (42g, yield 65.9%).
[0059] LC-MS(ESI): m / z=369.1 [M+H] +
[0060] Step 3: Compound 1C (42 g, 114 mmol) was dissolved in phosphorus oxychloride (300 mL) and reacted at 120° C. overnight. After the reaction was cooled to room temperature, it was concentrated under reduced pressure, and the resulting residue was slowly added to ice water (300 mL), and saturated aqueous sodium bicarbonate was added in small portions to adjust the pH to 6.0, and extracted with dichloromethane (500 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated, and the residue was separated by silica gel column chromatography (DCM:MeOH (v / v)=40:1) to obtain the target compound (12.7 g, 30% yield).
[0061] LC-MS(ESI): m / z=369.1 [M+H] + . 1 H NMR(400MHz,CDCl3)δ 7.48-7.32(m,5H),7.14(s,1H),6.80(s,1H),6.64(s,1H),5.23(s,2H),4.20(t,2H),3.96(s,3H),2.94(t,2H).
[0062] Step 4: 1D (8.2 g, 22.2 mmol) was dissolved in isopropyl alcohol (120 mL), 2,4,6-trimethylaniline (4.46 g, 33 mmol) was added, and the reaction was allowed to proceed for 24 hours at 90° C. after completion. After the reaction was cooled to room temperature, it was concentrated under reduced pressure, and the residue was added with saturated aqueous sodium bicarbonate solution (100 mL), extracted with dichloromethane (100 mL×3), the organic phases were combined, washed with saturated aqueous sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (DCM:MeOH (v / v)=20:1) to give compound 1E (8.3 g, yield 80%).
[0063] LC-MS(ESI): m / z=468.2 [M+H] + .
[0064] Step 5: Compound 1E (2.8 g, 6 mmol), 2-(2-bromoethyl)isoindoline-1,3-dione (9.15 g, 36 mmol), potassium carbonate (7.45 g, 54 mmol) and sodium iodide (5.4 g, 36 mmol) were added to dried 2-butanone (60 mL) in order, and the mixture was protected with nitrogen gas and reacted at 95 ° C for 48 hours. After the reaction was completed, the mixture was cooled to room temperature, filtered, the filter cake was washed with dichloromethane (80 mL), and the filtrate was concentrated under reduced pressure. The residue obtained was separated by silica gel column chromatography (petroleum ether: ethyl acetate (v / v) = 1:0 to 1:1) to obtain the target compound 1F (0.92 g, yield 24%).
[0065] LC-MS(ESI): m / z=641.2 [M+H] + .
[0066] Step 6: Compound 1F (0.92 g, 1.44 mmol) was dissolved in ethyl acetate (20 mL), palladium carbon (0.5 g) was added, and the mixture was reacted at room temperature for 1 hour under a hydrogen gas atmosphere. After the reaction was completed, the mixture was filtered, the filter cake was washed with methanol (30 mL), and the filtrate was concentrated under reduced pressure to obtain the target compound 1G (0.58 g, 73% yield).
[0067] LC-MS(ESI): m / z=551.2 [M+H] + .
[0068] Step 7: Compound 1G (0.58 g, 1.05 mmol) was dissolved in DMF (10 mL), potassium carbonate (0.29 g, 2.1 mmol) was added, and after uniform stirring, deuterated iodomethane (0.30 g, 2.1 mmol) was added dropwise, and the mixture was reacted at room temperature for 1 hour after the completion of the dropwise addition. After the reaction was completed, saturated saline (50 mL) was added and extracted with dichloromethane (50 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was separated by silica gel column chromatography (petroleum ether: ethyl acetate (v / v) = 1:0 to 1:1) to obtain compound 1H (0.52 g, yield 87%).
[0069] LC-MS(ESI): m / z=568.2 [M+H] + .
[0070] Step 8: Compound 1H (0.52 g, 0.92 mmol) was dissolved in chloroform (10 mL) and ethanol (10 mL), and hydrazine hydrate (0.3 g, 80 wt%) was added. After uniform stirring, the mixture was reacted at room temperature for 24 hours. After the reaction was completed, the mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 5:1) to obtain compound 1I (0.35 g, yield 87%).
[0071] LC-MS(ESI): m / z=438.1 [M+H] +
[0072] Step 9: Compound 1I (0.22 g, 0.50 mmol) was dissolved in water (10 mL), 1N hydrochloric acid (1 mL) was added, and the mixture was stirred uniformly. The mixture was then heated to 80°C, and an aqueous solution (1 mL) of potassium cyanate (81 mg, 1 mmol) was added dropwise to the reaction. After the addition was completed, the reaction was continued at 80°C for 2 h. The mixture was cooled to room temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added, and the mixture was extracted with dichloromethane (20 mL x 2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 10:1) to obtain compound 1 (0.12 g, yield 50%).
[0073] LC-MS(ESI): m / z=481.3 [M+H] + 1 H NMR(400MHz,CDCl3)δ 6.91(s,2H),6.68(s,2H),5.47(s,1H),5.25(br,2H),4.44(s,2H),4.08(s,2H), 3.75(s,3H),3.55(s,2H),2.94(s,2H),2.29(s,3H),2.09(s,6H),1.61(br,1H).
[0074] Example 2: (E)-1-(2-(2-((2,6-dimethyl-4-(trifluoromethyl)phenyl)imino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (Compound 2) [ka]
[0075] Step 1: 2A (50 g, 0.28 mol) was dissolved in water (150 mL), KCNO (8.1 g, 0.10 mol) was added, and hydrochloric acid solution (40 mL of concentrated hydrochloric acid dissolved in 150 mL of water) was added dropwise slowly. The reaction was warmed to reflux and stirred overnight. After the reaction was complete, it was cooled to 0° C., filtered, the filter cake was washed with cold water (150 mL), and the resulting filter cake was dried to give the title compound 2B (51 g, 82.3%).
[0076] LC-MS(ESI): m / z=225.2 [M+H] + .
[0077] Step 2: 2B (51 g, 0.22 mol) was dissolved in absolute ethanol (300 mL), diethyl malonate (50 g, 0.34 mol) and sodium ethoxide (47 g, 0.69 mol) were added sequentially, and the reaction was heated to reflux and stirred overnight. After the reaction was complete, it was cooled to room temperature and concentrated under reduced pressure to remove most of the ethanol, water (150 mL) was added to the residue, the pH was adjusted to 6.0 with dilute hydrochloric acid (5 M), filtered, and the filter cake was washed with cold water (150 mL) and dried to give the title compound 2C (45.0 g, 65.9%).
[0078] LC-MS(ESI): m / z=293.3 [M+H] + .
[0079] Step 3: 2C (20.0 g, 68.4 mmol) was dissolved in POCl3 (200 mL), heated to 100 °C, and stirred overnight. After the reaction was completed, it was cooled to room temperature, concentrated to 30 mL, slowly added with ice water (300 mL), adjusted to pH 6.0 with 5N aqueous sodium hydroxide solution, and extracted with dichloromethane (300 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was separated and purified by silica gel column (dichloromethane:methanol (v / v) = 20:1 to 10:1) to give the title compound 2D (11.5 g, 55%).
[0080] 1 H NMR(400MHz,DMSO-d6) δ 7.50(s,1H),7.27(s,1H),7.04(s,1H),4.06 - 4.03(m,2H),3.86 - 3.83(m,6H),2.98 - 2.95(m,2H). LC-MS(ESI): m / z=293.3 [M+H] + .
[0081] Step 4: 2E (3g, 9.46mmol), trimethylcyclotriboroxine (1.79g, 14.2mmol) were dissolved in ethylene glycol dimethyl ether (12mL), tetrakis(triphenylphosphine)palladium (1.09g, 0.95mmol), potassium carbonate (3.92g, 28.38mmol) were added in sequence, and the mixture was reacted at 100°C under a nitrogen gas atmosphere. After the reaction was completed, the reaction was stopped and the reaction was cooled to room temperature, and then concentrated under reduced pressure to remove most of the reaction solution. DCM (20mL) was added to the residue, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by a silica gel column (dichloromethane:methanol (v / v) = 20:1 to 10:1) to obtain the title compound 2F (0.42g, 25%).
[0082] LC-MS(ESI): m / z=190.2 [M+H] + .
[0083] Step 5: 2D (0.5 g, 1.71 mmol) was dissolved in isopropyl alcohol (12 mL), 2F (0.49 g, 2.57 mmol) was added, and the mixture was reacted at 90 ° C for 24 hours after completion. After the reaction was completed, the reaction was stopped, and the reaction was cooled to room temperature, and then concentrated under reduced pressure to remove most of the solvent. Saturated aqueous sodium bicarbonate solution (20 mL) was added to the residue, and the mixture was extracted with dichloromethane (20 mL × 3), and the organic phases were combined, washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was separated by silica gel column chromatography (DCM: MeOH (v / v) = 20: 1) to obtain compound 2G (0.65 g, yield 85%).
[0084] LC-MS(ESI): m / z=446.3 [M+H] + .
[0085] Step 6: Compound 2G (0.4 g, 0.9 mmol), 2-(2-bromoethyl)isoindoline-1,3-dione (0.69 g, 2.7 mmol), potassium carbonate (0.37 g, 2.7 mmol) and sodium iodide (0.41 g, 2.7 mmol) were mixed and dissolved in dry acetonitrile (20 mL), protected with nitrogen gas, and reacted at 120 ° C for 2 hours under microwave. After the reaction was completed, it was cooled to room temperature and filtered, the filter cake was washed with dichloromethane (20 mL), and the filtrate was concentrated under reduced pressure and then separated by silica gel column chromatography (petroleum ether: ethyl acetate (v / v) = 1:0 to 1:1) to obtain the target compound 2H (0.25 g, yield 45%).
[0086] LC-MS(ESI): m / z=619.3 [M+H] + .
[0087] Step 7: Compound 2H (0.25 g, 0.40 mmol) was dissolved in chloroform (10 mL) and ethanol (10 mL), and hydrazine hydrate (0.2 g, 80 wt%) was added. After stirring uniformly, the mixture was reacted at room temperature for 24 hours. After the reaction was completed, the mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 5:1) to obtain compound 2I (0.17 g, yield 89%).
[0088] LC-MS(ESI): m / z=489.1 [M+H] + .
[0089] Step 8: Compound 2I (0.17g, 0.36mmol) was dissolved in water (10mL), 1N hydrochloric acid (1mL) was added, and the mixture was stirred uniformly and then heated to 80°C. An aqueous solution (1mL) of potassium cyanate (81mg, 1mmol) was added dropwise to the system, and the reaction was continued for 2h after the completion of the addition. The mixture was cooled to room temperature, saturated aqueous sodium bicarbonate solution (10mL) was added, and the mixture was extracted with dichloromethane. The combined organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0-10:1) to obtain compound 2 (0.08g, yield 41%).
[0090] 1 H NMR(400MHz,Methanol-d4)δ 7.36(s,2H),6.88(s,1H),6.74(s,1H),5.38(s,1H),4.38 -4.35(s,2H),4.18-3.93(m,2H),3.86(s,3H),3.66(s,3H),3.56-3.53(m,2H),2.94-2.91(m,2H),2.16(s,6H). LC-MS(ESI): m / z=532.3 [M+H] + .
[0091] Example 3: (E)-1-(2-(2-((4-cyclopropyl-2,6-dimethylphenyl)imino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (Compound 3) [ka]
[0092] Step 1: Compound 3A (3g, 15.07mmol), cyclopropylboronic acid (1.94g, 22.67mmol) were dissolved in toluene (20mL) and water (5mL), and palladium acetate (0.34g, 1.51mmol), tricyclohexylphosphine (0.47g, 28.38mmol), and potassium phosphate (6.40g, 30.14mmol) were added in sequence, and the mixture was reacted at 100°C under a nitrogen gas atmosphere. After monitoring the completion of the reaction by TLC and LC-MS, the reaction was stopped, and the reaction was cooled to room temperature, and then concentrated under reduced pressure to remove most of the reaction solution. DCM (20mL) was added to the residue, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by a silica gel column (dichloromethane:methanol (v / v) = 20:1 to 10:1) to obtain the title compound 3B (0.70g, 29%).
[0093] LC-MS(ESI): m / z=162.2 [M+H] + .
[0094] Step 2: 2D (0.5 g, 1.71 mmol) was dissolved in isopropyl alcohol (12 mL), 3B (0.41 g, 2.57 mmol) was added, and the mixture was reacted at 90° C. for 24 hours after completion. After the reaction was completed, the mixture was cooled to room temperature, concentrated under reduced pressure, saturated aqueous sodium bicarbonate solution (20 mL) was added, and the mixture was extracted with dichloromethane (20 mL×3), and the combined organic phase was washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (DCM:MeOH (v / v)=20:1) to obtain compound 3C (0.50 g, 70% yield).
[0095] LC-MS(ESI): m / z=418.3 [M+H] + .
[0096] Step 3: Compound 3C (0.50 g, 1.20 mmol), 2-(2-bromoethyl)isoindoline-1,3-dione (0.92 g, 3.6 mmol), potassium carbonate (0.50 g, 3.6 mmol) and sodium iodide (0.54 g, 3.6 mmol) were mixed and dissolved in dry acetonitrile (20 mL) and reacted at 120 ° C for 2 hours under nitrogen gas atmosphere and microwave. After the reaction was completed, it was cooled to room temperature, filtered, the filter cake was washed with dichloromethane (20 mL), and the filtrate was concentrated under reduced pressure and then separated by silica gel column chromatography (petroleum ether: ethyl acetate (v / v) = 1: 0 to 1: 1) to obtain the target compound 3D (0.33 g, yield 47%).
[0097] LC-MS(ESI): m / z=591.3 [M+H] + .
[0098] Step 4: Compound 3D (0.33 g, 0.56 mmol) was dissolved in chloroform (10 mL) and ethanol (10 mL), and hydrazine hydrate (0.3 g, 80 wt%) was added. After stirring uniformly, the mixture was reacted at room temperature for 24 hours. After the reaction was completed, the mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 5:1) to obtain compound 3E (0.18 g, yield 70%).
[0099] LC-MS(ESI): m / z=461.2 [M+H] + .
[0100] Step 5: Compound 3E (0.18 g, 0.39 mmol) was dissolved in water (10 mL), 1N hydrochloric acid (1 mL) was added, and the mixture was stirred uniformly and then heated to 80°C. An aqueous solution (1 mL) of potassium cyanate (81 mg, 1 mmol) was added dropwise to the system, and stirring was continued for 2 h after the addition was completed. The mixture was cooled to room temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added, and the mixture was extracted with dichloromethane (20 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 10:1) to obtain compound 3 (0.07 g, yield 36%).
[0101] 1 H NMR(400MHz,Methanol-d4)δ 7.03-6.98(m,3H),6.79(s,1H),5.65(s,1H),4.39-4.36(m,2H),4.19-4.16(m,2H),3.91(s,3H),3.69(s,3H) ,3.56-3.52(m,2H),3.06-3.03(m,2H),2.27(s,6H),1.94-1.91(m,1H),1.16-0.94(m,2H),0.83-0.61(m,2H). LC-MS(ESI): m / z=504.3 [M+H] + .
[0102] Example 4: (E)-1-(2-(9-ethoxy-2-trimethylphenylimino)-10-methoxy-4-oxy-6,7-dihydro-2-hydro-pyrimidone[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (Compound 4) [ka]
[0103] Step 1: Compound 4A (77 mg, 0.17 mmol) (see patent WO 2021143843 for the synthesis of compound 4A) was dissolved in water (5 mL), potassium cyanate (48.3 mg, 0.6 mmol, 3.5 eq), dilute hydrochloric acid (concentrated HCl (43 ul, 0.51 mmol, 3 eq) diluted with water (5 mL) and added), and reacted at 100 ° C for 18 hours after completion. TLC / LCMS showed that the raw materials were completely reacted, the reaction was cooled to room temperature, extracted three times with dichloromethane (20 mL), the combined organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (dichloromethane:methanol (v / v) = 10: 1) to obtain compound 4 (81 mg, 0.16 mmol, 97% yield).
[0104] LC-MS(ESI): m / z=492.2 [M+H] + . 1 H NMR(400MHz,Chloroform-d)δ 6.94(s,2H),6.68(m,2H),5.49(s,1H),4.47(s,2H),4.15(m,2H),4.11(m,2H), 3.74(s,3H),3.58(s,2H),2.95(s,2H),2.30(s,3H),2.13(s,6H),1.49(m,3H).
[0105] Example 5: (E)-1-(2-(2-((4-fluoro-2,6-dimethylphenyl)imino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (Compound 5) [ka]
[0106] Step 1: 2D (0.5 g, 1.71 mmol) was dissolved in isopropyl alcohol (12 mL), 4-fluoro-2-methylaniline (0.32 g, 2.57 mmol) was added, and the mixture was reacted at 90 ° C for 12 hours after completion. After the reaction was completed, it was cooled to room temperature, concentrated under reduced pressure, and the residue was added with saturated aqueous sodium bicarbonate solution (20 mL), extracted with dichloromethane (20 mL × 3), and the combined organic phase was washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (DCM: MeOH (v / v) = 20: 1) to obtain compound 5A (0.57 g, yield 85%).
[0107] LC-MS(ESI): m / z=396.2 [M+H] + .
[0108] Step 2: Compound 5A (0.57 g, 1.5 mmol), 2-(2-bromoethyl)isoindoline-1,3-dione (1.15 g, 4.5 mmol), potassium carbonate (0.62 g, 4.5 mmol) and sodium iodide (0.69 g, 4.5 mmol) were mixed and dissolved in dry acetonitrile (20 m ), protected with nitrogen gas, and reacted at 120°C for 2 hours under microwave. After the reaction was completed, it was cooled to room temperature and filtered, the filter cake was washed with dichloromethane (20 mL), and the filtrate was concentrated under reduced pressure and then separated by silica gel column chromatography (petroleum ether: ethyl acetate (v / v) = 1:0 to 1:1) to obtain the target compound 5B (0.34 g, yield 40%).
[0109] LC-MS(ESI): m / z=569.2 [M+H] + .
[0110] Step 3: Compound 5B (0.34 g, 0.60 mmol) was dissolved in chloroform (10 mL) and ethanol (10 mL), and hydrazine hydrate (0.30 g, 80 wt%) was added. After uniform stirring, the mixture was reacted at room temperature for 12 hours. After the reaction was completed, the mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 5:1) to obtain compound 5C (0.17 g, yield 89%).
[0111] LC-MS(ESI): m / z=439.1 [M+H] + .
[0112] Step 4: Compound 5C (0.085 g, 0.2 mmol) was dissolved in water (10 mL), 1 N hydrochloric acid (1 mL) was added, and the mixture was stirred uniformly. The temperature was raised to 80°C, and an aqueous solution (1 mL) of potassium cyanate (81 mg, 1 mmol) was added dropwise to the system. After the addition was completed, the mixture was stirred for 2 h under these conditions. The mixture was cooled to room temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added, and the mixture was extracted with dichloromethane (20 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 10:1) to obtain compound 5 (0.09 g, yield 93%).
[0113] 1 H NMR(400MHz,CD3OD)δ 6.78(s,1H),6.74(s,1H),6.71(s,1H),6.64(s,1H),5.35(s,1H),4.26-4.23( m,2H),3.92-3.89(m,2H),3.76(s,3H),3.59(s,3H),3.45-3.42(m,2H),2.84- 2.81(m,2H),1.99(s,6H). LC-MS(ESI): m / z=482.3 [M+H] + .
[0114] Example 6: (E)-1-(2-(9-(benzyloxy)-2-(mesitylimino)-10-methoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (Compound 6) [ka]
[0115] Step 1: Compound 1F (0.2 g, 0.31 mmol) was dissolved in chloroform (10 mL) and ethanol (10 mL), hydrazine hydrate (194 mg, 3.1 mmol, 10 eq, 80% w / w) was added, and the mixture was allowed to react at room temperature overnight. TLC / LCMS showed that the reaction was complete, so the reaction was quenched with saturated aqueous sodium bicarbonate (30 mL), extracted with dichloromethane (40 mL x 2), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (dichloromethane:methanol = 10:1) to obtain product 6A (63 mg, 0.12 mmol, yield 40%).
[0116] Step 2: Compound 6A (63 mg, 0.12 mmol) was dissolved in water (5 mL), potassium cyanate (34 mg, 0.42 mmol, 3.5 eq) was added, concentrated hydrochloric acid (0.03 mL, 0.36 mmol, 3 eq) was added after dilution with water (5 mL), and the mixture was heated to 100 ° C. after completion and reacted overnight. TLC / LCMS showed that the reaction was completely reacted, and after cooling to room temperature, it was quenched with saturated aqueous sodium bicarbonate solution (20 mL), extracted with dichloromethane (20 mL × 2), and the combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain the product, which was separated and purified by silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain compound 6 (51 mg, 0.09 mmol, 77% yield).
[0117] LC-MS(ESI): m / z=554.3 [M+H] + . 1 H NMR(400MHz,CDCl3)δ 7.41-7.33(m,5H),6.92(s,2H),6.72(s,2H),5.48(s,1H),5.18(s,2H),4.44(m,2) H),4.06(m,2H),3.76(s,3H),3.56(m,2H),2.89(m,2H),2.30(s,3H),2.08(s,6H).
[0118] Example 7: (E)-1-(2-(2-(2,4,6-trimethylphenylimino)-9-methoxy-10-(methoxy-D3 deuterium)-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (Compound 7) [ka]
[0119] Step 1: Compound 2-(4-(benzyloxy)-3-methoxyphenyl)ethylamino (7A) (synthesized with reference to Bioorganic & Medicinal Chemistry, 21(4), 856-868.) (51.5g, 0.20mol) was dissolved in water (300mL), potassium cyanate (32.4g, 0.40mol) was added little by little, and after uniform stirring, 2N hydrochloric acid (240mL) was added dropwise. After the dropwise addition was completed, the mixture was refluxed overnight. It was cooled to 0℃, filtered, and the filter cake was rinsed with ice ethanol and dried to obtain the target compound 7B (38.0g, yield 63%).
[0120] LC-MS(ESI): m / z=301.2 [M+H] + .
[0121] Step 2: Compound 7B (38g, 0.13mol) was dissolved in anhydrous ethanol (300mL), diethyl malonate (27g, 0.17mol) was added, and after uniform stirring, sodium ethoxide (133g, 0.39mol, 20wt% in EtOH) was added dropwise, and after completion of the addition, the mixture was refluxed overnight. After the reaction was cooled to room temperature, it was concentrated under reduced pressure to 150mL, diluted with water (150mL), and adjusted to pH 6.0 with 5N hydrochloric acid, then filtered. The filter cake was washed with water (150mL) and dried to obtain the target compound 7C (42g, yield 90%).
[0122] LC-MS(ESI): m / z=369.1 [M+H] + .
[0123] Step 3: Compound 7C (42 g, 114 mmol) was dissolved in phosphorus oxychloride (300 mL) and reacted at 120° C. overnight. After the reaction was completed, it was cooled to room temperature and concentrated under reduced pressure. The residue was slowly added to ice water (300 mL), adjusted to pH=6.0 with saturated aqueous sodium bicarbonate, extracted with dichloromethane (500 mL×3), the combined organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated by silica gel column chromatography (DCM:MeOH (v / v)=40:1) to obtain the target compound 7D (12.7 g, 30% yield).
[0124] LC-MS(ESI): m / z=369.1 [M+H] + .
[0125] Step 4: 7D (0.82 g, 2.22 mmol) was dissolved in isopropyl alcohol (120 mL), 2,4,6-trimethylaniline (0.446 g, 3.3 mmol) was added, and the mixture was reacted at 90° C. for 24 hours after completion. After the reaction was completed, the mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was added with saturated aqueous sodium bicarbonate solution (100 mL), extracted with dichloromethane (100 mL×3), and the combined organic phase was washed with saturated aqueous sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (DCM:MeOH (v / v)=20:1) to obtain compound 7E (0.53 g, 55% yield).
[0126] LC-MS(ESI): m / z=468.2 [M+H] + .
[0127] Step 5: Compound 7E (0.53 g, 1.13 mmol), bromoacetonitrile (0.54 g, 3.9 mmol), and lithium carbonate (0.69 g, 3.3 mmol) were mixed and dissolved in dry acetonitrile (10 mL). The mixture was reacted at 90°C for 18 hours under a nitrogen gas atmosphere. After the reaction was completed, the mixture was cooled to room temperature and filtered. The filter cake was washed with dichloromethane (80 mL). The filtrate was concentrated under reduced pressure, and the crude product was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 20:1) to obtain the target compound 7F (0.5 g, yield 42%).
[0128] LC-MS(ESI): m / z=507.3 [M+H] + .
[0129] Step 6: Compound 7F (0.5 g, 1.0 mmol) was dissolved in ethyl acetate (50 mL), palladium carbon (0.3 g, 10% w / w) was added, and the mixture was reacted at room temperature for 3 hours under a hydrogen gas atmosphere. TLC / LCMS showed that the raw materials had completely reacted, and the palladium carbon was removed by filtration, the filter cake was washed twice with ethyl acetate (20 mL), and the filtrate was concentrated under reduced pressure. The crude product obtained was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 7G (0.21 g, 58% yield).
[0130] LC-MS(ESI): m / z=417.3 [M+H] + .
[0131] Step 7: Compound 7G (210 mg, 0.64 mmol) was dissolved in DMF (20 mL), deuterated iodomethane (186 mg, 1.28 mmol), potassium carbonate (177 mg, 1.28 mmol) were added in sequence, and the mixture was stirred at room temperature for 5 hours. TLC / LCMS showed that the raw material had reacted completely, so the reaction was quenched with saturated saline (30 mL), extracted with dichloromethane (40 mL x 2), the combined organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3: 1) to give compound 7H (180 mg, 64% yield).
[0132] LC-MS(ESI): m / z=434.2 [M+H] + .
[0133] Step 8: Compound 7H (180 mg, 0.414 mmol) was added to ethanol (10 mL), Raney nickel (150 mg) was added little by little at room temperature, hydrazine hydrate (1 mL) was added, and the mixture was heated to 60° C. and reacted for 1 hour. After the reaction was completed, the mixture was cooled to room temperature, and the filtrate was concentrated under reduced pressure to obtain compound 7I (0.12 g, 66% yield), which was used directly in the next step without further purification.
[0134] LC-MS(ESI): m / z=438.2 [M+H] + .
[0135] Step 9: Compound 7I (0.12 g, 0.23 mmol) was dissolved in water (10 mL), 1 N hydrochloric acid (1 mL) was added, and the mixture was stirred uniformly. The temperature was raised to 80°C, and an aqueous solution (1 mL) of potassium cyanate (81 mg, 1 mmol) was added dropwise to the system. After the addition was completed, the mixture was stirred for 2 h under these conditions. The mixture was cooled to room temperature, saturated sodium bicarbonate (10 mL) was added, and the mixture was extracted with dichloromethane (30 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (dichloromethane:methanol (v / v) = 1:0 to 10:1) to obtain compound 7 (0.08 g, yield 41%).
[0136] LC-MS(ESI): m / z=481.3 [M+H] + . 1 H NMR(400MHz,Methanol-d4)δ 6.80(s,2H),6.77(s,1H),6.65(s,1H),5.40(s,1H),4.25 -4.22(m,2H),3.91-3.88(m,2H),3.76(s,3H),3.45-3.42(m,2H),2.83-2.81(m,1H),2.17(s,3H),1.96(s,6H).
[0137] Biological testing: 1. The inhibitory activity of the compounds against PDE 3A and PDE 4B2 enzymes was detected in vitro.
[0138] Test materials: Envision 2104 Multilabel Reader (PerkinElmer) Black 96-well Plate(Cat#6005540,PerkinElmer) PDE3A Assay Kit(BPS,Cat. 79736),PDE4B2 Assay Kit(BPS,Cat. 60343) PDE3A recombinant enzyme PDE4B2 recombinant enzyme FAM-Cyclic-3′,5′-AMP PDE assay buffer Binding Agent Binding Agent Diluent (cAMP)
[0139] Experimental steps: 1) Prepare FAM cAMP working solution: 20 μL of FAM-Cyclic-3′,5′-AMP stock was added to 1980 μL of PDE assay buffer. 25 μL / well was added to all wells.
[0140] 2) Preparation of compound solution: First, the target compound was dissolved in DMSO to make a 10 mM stock solution. The compound stock solution was diluted with DMSO to make a 100X Top Dose dilution solution. Next, 5μL of the 100X Top Dose dilution solution was taken and added to 45μL of PDE assay buffer to prepare a compound Top Dose working solution. Then, it was diluted with 10% DMSO-containing PDE assay buffer to prepare compound working solutions of each concentration. 5μL / well was added to the compound wells. 5μL / well of 10% DMSO-containing PDE assay buffer was added to the control wells.
[0141] 3) Preparation of PDE enzyme solution: PDE3A and PDE4B2 enzyme stock solutions were diluted to 150 pg / μL and 50 pg / μL, respectively, using PDE assay buffer, and added to all compound wells and vehicle control wells at 20 μL / well. 20 μL of PDE assay buffer was added to blank control wells.
[0142] 4) The reaction was allowed to proceed at room temperature for 1 hour.
[0143] 5) Preparation of binding agent: 80 μL of binding agent was taken and added to 7920 μL of binding agent diluent and mixed uniformly. 100 μL / well was added to all wells.
[0144] 6) The reaction was allowed to proceed at room temperature for 1 hour.
[0145] 7) FP was read with Envision.
[0146] 8) Raw data calculation formula: %Inhibition rate=(FP V -FP S ) / (FP V -FP B )×100% FP S = Sample FP FP V =Vehicle Control FP FP B =Blank control FP.
[0147] Using graphpad, nonlinear regression was performed on the log [dose]-inhibitory rate and IC 50 was calculated.
[0148] Test Results: The compounds of the present invention have excellent PDE 3 and PDE 4 inhibitory activity, with IC values of less than 500 nM. 50 Some excellent compounds have IC 50 <200 nM, with some even better compounds having IC 50 <100 nM, and some of the more potent compounds have IC 50 <50 nM, e.g., for PDE 3, the IC 50 is 0.15 nM, and the IC 50 is 0.17 nM. The test results of some compounds are listed in the table below.
[0149] [Table 1]
[0150] A: 0 nM <IC 50 ≦50nM, B: 50nM <IC 50 ≦100nM, C: 100nM <IC 50 ≦200nM, D: 200nM <IC 50 , NT: No test.
[0151] 2. Study on the inhibitory effect of compounds on methacholine-induced bronchoconstriction in guinea pigs In this study, male guinea pigs were selected as test animals, and RPL554, compound 1 and compound 7 were orally administered at a dose of 10 mg / kg to the treatment group, and an equal volume of solvent was administered to the control group. 2 h, 4 h and 6 h after drug exposure, the animals were placed in the aerosol chamber of the WBP device, and after the animals were acclimatized, they were allowed to inhale 300 uL of acetylcholine solution (0.5 mg / mL) by nebulization. After the end of methacholine (Mch) exposure, the Penh value was recorded continuously for 7 minutes. The percentage of contraction inhibition by the compound was calculated based on the Penh value.
[0152] The inhibition rate of each compound against bronchoconstriction at an oral dose of 10 mg / kg is shown in the following table.
[0153] [Table 2]
[0154] 3. Guinea pig tracheal ring experiment Experimental method: Take guinea pig tracheal rings and place them in a specific culture medium (Krebs-Henseleit), equilibrate the tracheal rings with 1g tension for 40 minutes, add a certain amount of carbachol to achieve 100% contraction of the tracheal rings, add 1x10^6M of the drug, and detect the change in the contraction tension of the tracheal rings.
[0155] Test conditions: a single dose of 10 μM, with 4 samples in each group, and the 50% inhibitory effect onset time and 50% inhibitory recovery time at that dose were calculated.
[0156] [Table 3]
[0157] Conclusion: Compound 7 has a shorter onset time and longer duration of effect than RPL554 in this experiment, and its inhibition rate on tracheal contraction at 6.75 h is higher than that of RPL554.
[0158] Note: The RPL554 structure is [ka] It is.
Claims
1. A compound of formula (I), a stereoisomer, solvate, or a pharma- ceutically acceptable salt thereof, [Formula 1] Here, R 1 , R 2 , R a and R b are each independently H, deuterium, halogen, CN, OH, or NH 2 , -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl) 2 , -OC 1-4 Alkyl group, -O(CH 2 ) m C 3-6 Cycloalkyl groups, -O(CH 2 ) m Phenyl group, —O(CH 2 ) m - a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, S, and O; -O(CH 2 ) m - a 5-6 membered heteroaryl group containing 1-3 selected from N, S, O heteroatoms; C 1-4 Alkyl group, -(CH 2 ) m C 3-6 Cycloalkyl groups, -(CH 2 ) m Phenyl group, -(CH 2 ) m - a 4-7 membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, S, O, or -(CH 2 ) m -5-6 membered heteroaryl groups containing 1-3 selected from N, S, O heteroatoms, said alkyl, phenyl, cycloalkyl, heterocycloalkyl and heteroaryl groups optionally containing deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4Alkoxy group, halogenated C 1-4 Alkoxy group, CN, NH 2 , -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl) 2 and OH; Selectable, R 1 and R 2 and the atoms to which they are linked, taken together, form a 5-7 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 4-7 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C 1-4 Alkyl groups, halogenated C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R 3 , R 4 , R 5 , R 6 are each independently H, deuterium, halogen, or C 1-4 Alkyl group, -(CH 2 ) m C 3-6 Cycloalkyl groups, the alkyl and cycloalkyl groups optionally containing deuterium, halogen, CN and NH 2 is substituted with 1 to 3 groups selected from Selectable, R 3 and R 4 , or R 5 and R 6 are C together with the carbon atoms connected to them. 3-6 Forming a cycloalkyl group, X is CO or SO 2 and Ring A is a phenyl group, C 9-10 a fused carbocyclic ring or a 5-6 membered heteroaryl group containing 1-3 selected from N, S, O heteroatoms; L 1 is C 1-6 an alkylene group, the alkylene group optionally containing deuterium, halogen, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R 7 is H, C 1-4 Alkyl group or -(CH 2 ) m C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups optionally containing deuterium, halogen, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R 8 and R 9 are each independently H, C 1-4 Alkyl group and C 3-6 is a cycloalkyl group, Selectable, R 8 and R 9 together with the N atom to which they are attached form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms, said heterocycle optionally being selected from ═O, deuterium, halogen, C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; Each R 10 are each independently H, a halogen, CN, or NH 2 , -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl) 2 , O.H., C. 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -(CH 2 ) m -C 3-6 Cycloalkyl group, —O—C 3-6 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl groups, CN, NH 2 , -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl) 2 and OH; n is 0, 1, 2, 3 or 4; each m is independently 0, 1, 2, 3, or 4; As a condition, [chemical 2] but [C3] If R 10 ', R 10 '', R 10 ''' is R 10 and the compound satisfies: (i) R 1 and R 2 is not a methoxy group at the same time, or (ii) R 3 , R 4 , R 5 , R 6 is not H at the same time, or (iii) R 10 "'' is not H or a methyl group, the compound, a stereoisomer, solvate, or a pharma- ceutically acceptable salt thereof.
2. R 1 , R 2 , R a and R b are each independently H, deuterium, halogen, CN, OH, or NH 2, -NHC 1-4 Alkyl group, -N(C 1-4 Alkyl) 2 , -OC 1-4 Alkyl group, -O(CH 2 ) m C 3-6 Cycloalkyl groups, -O(CH 2 ) m - a 4- to 7-membered heterocycloalkyl group containing 1 to 3 selected from N, S, and O heteroatoms; 1-4 Alkyl group, -(CH 2 ) m C 3-6 A cycloalkyl group, or -(CH 2 ) m - 4-7 membered heterocycloalkyl groups containing 1-3 selected from N, S, O heteroatoms, said alkyl, cycloalkyl and heterocycloalkyl groups optionally containing deuterium, halogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 is further substituted with 1 to 3 groups selected from an alkoxy group; Selectable, R 1 and R 2 and the atoms to which they are linked, taken together, form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 5-6 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C 1-4 Alkyl groups, halogenated C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R 3 , R 4 , R 5 , R 6 are each independently H, deuterium, a halogen, or C 1-4 alkyl groups, the alkyl groups optionally containing deuterium, halogen, CN and NH 2 is substituted with 1 to 3 groups selected from Ring A is a phenyl group, [C4] , a pyridyl group, a pyrimidinyl group, a thienyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group or an isoxazolyl group, L 1 is C 2-4 an alkylene group, the alkylene group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R 7 is H or C 1-4 an alkyl group, the alkyl group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R 8 and R 9 are each independently H, C 1-4 Alkyl group and C 3-6 is a cycloalkyl group, Selectable, R 8 and R 9 together with the N atom to which they are attached form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms, said heterocycle optionally being selected from ═O, deuterium, halogen, C 1-4 Alkyl group and C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; Each R 10 are each independently H, halogen, CN, or C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 substituted with 1 to 3 groups selected from alkyl groups and CN; 2. The compound of claim 1, or a stereoisomer, solvate, or pharma- ceutically acceptable salt thereof, wherein p is 1 or 2.
3. The compound has the structure of Formula II: [C5] R 1 , R 2 , R a and R b are each independently H, deuterium, halogen, CN, OH, or -OC 1-4 Alkyl group, -O(CH 2 ) m C 3-6 Cycloalkyl group, C 1-4 Alkyl group, or -(CH 2 ) m C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups optionally containing deuterium, halogen, C 1-4 Alkyl group, C 1-4 Alkoxy group, deuterated C 1-4 Alkyl groups, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 is further substituted with 1 to 3 groups selected from an alkoxy group; Selectable, R 1 and R 2 and the atoms to which they are linked, taken together, form a 5-6 membered heterocycle containing 1-3 selected from N, S, O heteroatoms or C 5-6 forming a carbocycle, the heterocycle and the carbocycle optionally containing deuterium, halogen, C 1-4 Alkyl groups, halogenated C 1-4 Alkyl group and C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; R 3 , R 4are each independently H, deuterium, a halogen, or C 1-4 an alkyl group, said alkyl group being optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br and I; Ring A is a phenyl group, [C6] , thienyl, thiazolyl, isothiazolyl, oxazolyl or isoxazolyl; R 7 is H or C 1-3 an alkyl group, the alkyl group optionally containing deuterium, halogen, C 1-4 Alkoxy group, deuterated C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; Each R 10 are each independently H, halogen, CN, or C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-4 Cycloalkyl group or C 1-4 and an alkoxy group, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and alkoxy groups are optionally deuterium, halogen, C 1-4 substituted with 1 to 3 groups selected from alkyl groups and CN; 3. The compound of claim 2, or a stereoisomer, solvate, or pharma- ceutically acceptable salt thereof, wherein q is 1, 2, or 3.
4. R 1 , R 2 , R a and R b are each independently H, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, or —O(CH 2 ) m A cyclopropyl group, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a -(CH 2 ) mcyclopropyl, wherein said methoxy, ethoxy, propoxy, isopropoxy, cyclopropyl, methyl, ethyl, propyl, isopropyl and cyclopropyl groups are optionally further substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated methoxy, deuterated ethoxy, deuterated propoxy, halogenated methoxy, halogenated ethoxy and halogenated propoxy; Selectable, R 1 and R 2 and the atoms connected thereto, taken together, [C7] and optionally substituted with 1 to 2 groups selected from deuterium, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, halogenated methyl, halogenated ethyl and halogenated propyl groups; R 3 , R 4 are each independently H, deuterium, F, Cl, Br, I, a methyl group, an ethyl group, or a propyl group, the methyl group, the ethyl group, or the propyl group being optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, and I; Ring A is a phenyl group, [C8] , a thienyl group or a thiazolyl group; R 7 is H, a methyl group, an ethyl group, a propyl group or an isopropyl group, the methyl group, the ethyl group, the propyl group or the isopropyl group being optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, a methoxy group, an ethoxy group, a propoxy group, a deuterated methyl group, a deuterated ethyl group, a deuterated propyl group, a deuterated methoxy group, a deuterated ethoxy group, a deuterated propoxy group, a halogenated methoxy group, a halogenated ethoxy group and a halogenated propoxy group; Each R 10are each independently H, F, Cl, Br, I, CN, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, vinyl, propenyl, allyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, methoxy, ethoxy or propoxy, and the methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, vinyl, propenyl, allyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, methoxy, ethoxy and propoxy groups are optionally substituted with 1 to 3 groups selected from deuterium, F, Cl, Br, I, methyl, ethyl, propyl and CN; The compound of claim 3, or a stereoisomer, solvate, or pharma- ceutically acceptable salt thereof, wherein q is 2 or 3.
5. The compound is [C9] [C10] 2. The compound of claim 1, wherein the compound is selected from one of the structures:
6. A composition comprising a compound according to any one of claims 1 to 5, or a stereoisomer, solvate, or pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier and / or excipient.
7. Use of a compound according to any one of claims 1 to 5, a stereoisomer, a solvate, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 6, in the manufacture of a medicament for treating / preventing a PDE3 / 4 mediated disease.
8. The use according to claim 7, wherein the PDE3 / 4 mediated disease is selected from COPD and asthma.
Citation Information
Patent Citations
pyrimido[6,1-a]isoquinolin-4-one derivatives
JP2002540207A
Fused tricyclic compounds as dual PDE3 / PDE4 inhibitors
JP2021532088A
